OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Rheumatology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
A cursed goodbye kiss from severe acute respiratory syndrome-coronavirus-2 to its pediatric hosts: multisystem inflammatory syndrome in children	91
Recent advances in immunometabolism in rheumatic diseases	59
Epidemiology of systemic vasculitis	52
Complications of severe acute respiratory syndrome coronavirus 2 infection in children	52
Quo vadis reactive arthritis?	45
Editorial introduction	40
Is it time to move on from pelvic radiography as the first-line imaging modality for suspected sacroiliitis?	35
Go or no-go for treat-to-target in axial spondyloarthritis?	30
Epidemiology of systemic vasculitis	30
Imaging in pediatric spondyloarthritis	30
Chimeric antigen receptor T-cell therapy in rheumatology: B-cell depletion 2.0	28
Persistent hand pain despite adequate immunosuppression? The distinct value of occupational therapy in the era of biologics	27
An update on topical therapies for psoriasis	27
Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit	24
Current views on lupus in children	24
What is PFAPA syndrome? Genetic clues about the pathogenesis	22
Nonsteroidal anti-inflammatory drugs and cardiovascular disease risk in spondyloarthritis-spectrum diseases	22
Human genetics of Whipple's disease	21
Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate	21
The impact of dietary interventions in psoriatic arthritis	21
Metabolic perturbations in systemic sclerosis	21
Educational needs and challenges in axial spondyloarthritis	20
Integrating genetic and social factors to understand health disparities in lupus	19
Not all benign: disease course, complications, and sequalae of chronic recurrent multifocal osteomyelitis in children	18
Neurovascular dysregulation in systemic sclerosis: novel insights into pathophysiology, diagnosis, and treatment utilizing invasive cardiopulmonary exercise testing	17

Contribution of keratinocytes to dermal fibrosis	17
Autologous hematopoietic stem cell transplant for systemic sclerosis associated interstitial lung disease	16
Tocilizumab in giant cell arteritis: an update for the clinician	16
Autoantibodies in rheumatoid arthritis – rheumatoid factor, anticitrullinated protein antibodies and beyond	16
Giant cell arteritis: update on pathogenesis and clinical implications	16
Novel therapies in juvenile idiopathic arthritis	16
Current approach to muscle imaging in myositis	16
Urticarial vasculitis	16
Update on antineutrophil cytoplasmic autoantibody vasculitis in children	15
Blood and urine biomarkers in osteoarthritis – an update on cartilage associated type II collagen and aggrecan markers	15
AI am the future: artificial intelligence in pediatric rheumatology	14
Polymyalgia rheumatica and giant cell arteritis: diagnosis and management	14
Navigating the complexity of pain in psoriatic arthritis and axial spondyloarthritis	14
Uveitis in Behçet disease - an update	14
Optimizing reproductive health management in lupus and Sjogren's syndrome	13
Should CAR-T cells be used as monotherapy?	13
The complement system in antineutrophil cytoplasmic antibody-associated vasculitis: pathogenic player and therapeutic target	12
Biomarker discovery in psoriatic disease	12
Update on treatment responses and outcome measure development in chronic nonbacterial osteomyelitis	12
Out of the shadow of interleukin-17A: the role of interleukin-17F and other interleukin-17 family cytokines in spondyloarthritis	12
Juvenile Behçet syndrome: a contemporary view and differential diagnosis in pediatric practice	11
Insights into origins and specificities of autoantibodies in systemic sclerosis	11
Editorial introduction	11
The safety of glucocorticoids in the treatment of inflammatory rheumatic disease: new evidence	10
Diagnostic delay in axial spondyloarthritis – a past or current problem?	10
The role of immunomodulatory medications in the treatment of COVID-19	10
Recent findings in idiopathic inflammatory myopathies with potential diagnostic and therapeutic implications	9
Osteoporosis epidemiology using international cohorts	9
Rheumatologic immune checkpoint inhibitor-related adverse events	9
Transcriptomics data: pointing the way to subclassification and personalized medicine in systemic lupus erythematosus	9
Inflammatory back pain: a concept, not a diagnosis	9
Twenty years of clinical trials in axial spondyloarthritis: what can we learn for the future?	9
The dynamic organelle primary cilia: emerging roles in organ fibrosis	9
Editorial introductions	9
Review of publications evaluating opioid use in patients with inflammatory rheumatic disease	8
Medium-vessel and large-vessel vasculitis in children	8
New developments related to lung complications in pediatric rheumatic disease	8
When to stop medication in juvenile idiopathic arthritis	8
A treat-to-target approach is needed for Behçet's syndrome	8
Editorial introductions	8
Axial spondyloarthritis guidelines – aiming for maximum impact	7
Insights into the molecular landscape of osteoarthritis in human tissues	7
Editorial introductions	7
Diagnosis and management of primary heart involvement in systemic sclerosis	7
Editorial introductions	7
Novel imaging techniques for sacroiliac joint assessment	7
Dual-energy computed tomography in crystalline arthritis: knowns and unknowns	7
The impact of the COVID-19 pandemic on the field of pediatric rheumatology	7
Scleroderma autoantibodies in guiding monitoring and treatment decisions	7
Polymyositis: does it really exist as a distinct clinical subset?	7